Bionano Genomics (BNGO) stock soared 8.28% in intraday trading on Tuesday, outperforming the broader market. The rally was driven by the company's announcement of a debt restructuring deal and a lower conversion price for its outstanding convertible debentures.
According to the announcement, Bionano Genomics agreed to settle and amend its senior secured convertible debentures due in May 2024. The key changes include deferring the December 2024 amortization payment, reducing monthly payments from January to July 2025, and increasing payments starting in August 2025 until the debt is fully paid.
Furthermore, the company decreased the conversion price of the debentures from $2 to $0.27 per share and agreed to issue 5 million common shares to the debtholders. This move was seen as a positive development by investors, as it improves the company's financial flexibility and reduces the potential dilution impact on existing shareholders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。